Literature DB >> 12919096

Association of humoral immunity and bronchiolitis obliterans syndrome.

Cynthia M Magro1, Patrick Ross, Moira Kelsey, W James Waldman, Amy Pope-Harman.   

Abstract

Animal studies have shown that blockade of complement may reduce the severity of and/or prevent the development of bronchiolitis obliterans syndrome (BOS), suggesting a role for complement activation. We explored the hypothesis that humoral immunity plays a role in the evolution of BOS. Thirteen unilateral lung transplant patients with BOS defined the patient population. Fresh frozen tissue was analyzed for deposition of C1q, C4d, C5b-9 and immunoglobulin (IgG, IgM, IgA). An indirect immunofluorescent assay was also conducted with patient serum against cytospins of the pulmonary endothelium. In each case the biopsies showed a microvascular injury syndrome involving the bronchial wall characterized by one or more of hemorrhage, fibrin deposition, and endothelial cell necrosis. Other features included bronchial epithelial and chondrocyte necrosis. The end-stage lesion was a thinned bronchial epithelial lining mural fibrosis. Immunofluorescent analysis showed deposition of C1q, C3, C4d, C5b-9, and immunoglobulin in the bronchial epithelium, chondrocytes, basement membrane zone of the bronchial epithelium, and bronchial wall microvasculature. The indirect antiendothelial cell antibody assay was positive in all tested. Humoral immunity may play a role in the pathogenesis of BOS; the antigenic targets include the bronchial wall microvasculature, bronchial epithelium, and chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919096     DOI: 10.1034/j.1600-6143.2003.00168.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

Review 1.  Pros and cons for C4d as a biomarker.

Authors:  Danielle Cohen; Robert B Colvin; Mohamed R Daha; Cinthia B Drachenberg; Mark Haas; Volker Nickeleit; Jane E Salmon; Banu Sis; Ming-Hui Zhao; Jan A Bruijn; Ingeborg M Bajema
Journal:  Kidney Int       Date:  2012-02-01       Impact factor: 10.612

Review 2.  [Lung transplantation and rejection. Basic principles, clinical aspects and histomorphology].

Authors:  J Wohlschläger; U Sommerwerck; D Jonigk; J Rische; H A Baba; K M Müller
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

3.  Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome.

Authors:  H J Huang; R D Yusen; B F Meyers; M J Walter; T Mohanakumar; G A Patterson; E P Trulock; R R Hachem
Journal:  Am J Transplant       Date:  2008-09-10       Impact factor: 8.086

Review 4.  Complement-mediated microvascular injury leads to chronic rejection.

Authors:  Mohammad A Khan; Mark R Nicolls
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  Effector immune cells in chronic lung allograft dysfunction: A systematic review.

Authors:  Saskia Bos; Andrew J Filby; Robin Vos; Andrew J Fisher
Journal:  Immunology       Date:  2022-03-01       Impact factor: 7.215

6.  Soluble CD59 is a Novel Biomarker for the Prediction of Obstructive Chronic Lung Allograft Dysfunction After Lung Transplantation.

Authors:  Kevin Budding; Eduard A van de Graaf; Tineke Kardol-Hoefnagel; Johanna M Kwakkel-van Erp; Bart D Luijk; Erik-Jan D Oudijk; Diana A van Kessel; Jan C Grutters; C Erik Hack; Henderikus G Otten
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.